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Foot and mouth disease virus (FMDV) is the cause of a widespread infectious disease affecting cloven-hoofed animals. It
is controlled by vaccination with immune-inactivated virus grown in tissue culture. However, peptide vaccines represent a
safer alternative to the current virus-inactivated immunogens. Their design requires the identification and evaluation of the
sequences recognized by T- and B-lymphocytes. Four structural proteins, VP1, VP2, VP3, and VP4, comprise the viral capsid
of the FMDV, but only VP1 has been extensively studied regarding the existence of relevant T-cell epitopes. Here, we utilize
a murine model to present a functional T-cell epitope mapping on the complete sequences of VP2, VP3, and VP4 of FMDV
O1 Campos. We used two in vitro assays to describe 13 amino acid sequences, each one of them including at least one T-cell
epitope. The in vivo T-cell helper function of these sequences was studied in an adoptive cell-transfer assay in mice.
Immunization experiments with a fusion peptide containing one of the sequences characterized were also done comparing
the helper activity of this sequence with other T-cell epitopes included in the major immunogenic region of VP1. © 2000
Academic PressIntroduction. Foot and mouth disease virus (FMDV) is
responsible for a widely distributed and very contagious
febrile illness affecting cattle and other biungulated spe-
cies and having an important economic impact. The
sanitary control of this disease resides in the extensive
vaccination of all susceptible individuals (1). Conven-
tional FMDV vaccines are formulated with inactivated
virus, requiring the production of massive amounts of the
infectious agent. This production procedure, although
commonly employed, represents a serious risk of viral
dispersion and is completely inadequate for those coun-
tries where the disease is controlled or eradicated (1, 2).
As an alternative, the development of synthetic vac-
cines containing discrete selected epitopes would avoid
the manipulation of the infectious virus. Moreover, pep-
tide vaccines do not present safety risks such as rever-
sion or persistence (3), incomplete inactivation (2), or
even integration into the host cell genome as in the case
of naked DNA vaccines (4). The association of these
synthetic immunogens with different adjuvants has im-
proved the duration of the response (5), as well as the
delivery and presentation of the antigen (6), allowing the
modulation of the immune pathways toward protective
responses (7). Particularly in foot and mouth disease,
synthetic peptide vaccines have also been able to confer
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 54 11 4621 1743. E-mail: asadir@inta.gov.ar.
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
234a broader heterotypic protection than those formulated
with the whole inactivated virus (8). However, peptide
vaccines may also result in poor immunogens (9, 10). For
this reason, it is essential to detect and evaluate the
importance of the sequences of amino acid residues
recognized by T- and B-lymphocytes in order to induce
an effective immunity (11–14).
Four different structural proteins, VP1, VP2, VP3, and
VP4, comprise the viral capsid of FMDV. Although exten-
sive studies on the existence of T-cell epitopes were
carried out on the most immunogenic of those proteins,
VP1 (15–22), very few reports were presented regarding
the existence and relevance of T-cell epitopes in the
other three structural proteins (23, 24). The results ob-
tained in cattle upon vaccination with synthetic peptides
containing only VP1 epitopes were in many cases insuf-
ficient in terms of the immune response (10, 18) or the
protection achieved in vaccination trials (9). We consider
that this situation makes the study of T-cell epitopes
within the other structural proteins particularly relevant.
Results. A set of 33 peptides comprising the complete
amino acid sequences of the FMDV O1C structural pro-
teins VP2, VP3, and VP4 (Chiron Corp., USA) was em-
ployed to perform the experiments here described. Pep-
tides were 20 residues long and presented 4 residues
overlapping between contiguous sequences (Table 1).
Each peptide was separately used to immunize groups
of three adult male BALB/c mice (60–90 days old). Vac-
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235RAPID COMMUNICATIONcines for each sequence were formulated as water-in-oil
emulsions containing 60 mg of peptide/dose in the aque-
us phase. Mice received three intraperitoneal immuni-
ations on days 0, 30, and 60 and their sera and spleen
ells were extracted 3 days after the last vaccination.
Antibody response to the synthetic peptides. The first
pproach to detect the presence of T-cell epitopes was
ased on the assumption that only peptides harboring
unctional T epitopes would be able to elicit an antibody
esponse to themselves when inoculated into naive mice
n the absence of foreign T-cell epitopes. ELISA plates
ere coated with each individual peptide (0.75 mg/well),
and sera from the animals immunized with the corre-
sponding peptide were tested for the presence of spe-
cific antibodies against each sequence, as described
(20). The results showed that 12 sequences (peptides
2.4, 2.8, 2.9, 2.11, 2.12, 2.13, 3.6, 3.9, 3.11, 3.12, 3.13, and 4.2)
were able to induce specific antibodies to themselves,
therefore demonstrating the presence of at least one
T-cell and one B-cell epitope in the tested peptides
(Table 1 and Fig. 1A). A capture ELISA using intact FMDV
particles as antigen was performed according to Pe´rez
Filgueira et al. (25) and all immune sera obtained from
the peptide-immunized mice were completely unable to
recognize the whole viral particle (Fig. 1A). In the same
way, a pool of sera from FMDV O1C-infected mice failed
to recognize any of the peptides when they were ad-
sorbed to the plate in a direct ELISA (data not shown).
Both results indicate that the B-cell epitopes present in
these peptides were not immunologically relevant in the
anti-FMDV antibody response, perhaps because they are
not exposed in the virus particle.
In vitro lymphoproliferation assays. As a second crite-
rion to confirm the existence of these putative T-cell
epitopes, spleen cells from peptide-immunized mice
were used in an in vitro antigen-driven lymphoprolifera-
T
Peptides Employed in the Experiments a
of the O1 Campos FMDV Str
Peptide VP and residue position Peptide
4.1 VP4 1–20 2.7
4.2 VP4 17–36 2.8
4.3 VP4 33–52 2.9
4.4 VP4 49–68 2.10
4.5 VP4 65–84 2.11
2.1 VP2 1–20 2.12
2.2 VP2 17–36 2.13
2.3 VP2 33–52 2.14
2.4 VP2 49–68 3.1
2.5 VP2 65–84 3.2
2.6 VP2 81–100 3.3tion assay (ADLA), as described by Zamorano et al. (20).
Single spleen cell suspensions (2 3 105 cells/ml) werecultured for 96 h in the presence of medium alone or with
the homologous peptide diluted at concentrations be-
tween 20 and 1 mM. A pulse of [methyl-3H]thymidine
(Amersham Life Science, UK) was added to the cells
during the last 18 h of culture. Cells were harvested and
the amount of incorporated label was measured as
counts per minute (cpm) in a liquid scintillation counter
(Wallac, Finland). Eleven sequences (peptides 2.8, 2.9,
2.11, 2.12, 2.13, 3.6, 3.7, 3.9, 3.11, 3.12, and 3.13) of the 33
tested were able to activate the proliferation of spleen
lymphocytes from mice immunized with the homologous
sequence (Fig. 1A). As expected, 10 of these sequences
(peptides 2.8, 2.9, 2.11, 2.12, 2.13, 3.6, 3.9, 3.11, 3.12, and
3.13) coincided with those already detected by ELISA,
thus confirming the previous results.
Adoptive cell transfer assays. As we previously re-
ported, B-cells obtained from mice immunized with a low
dose of inactivated FMDV (0.1 mg) and then transferred to
mmunosuppressed animals are unable to produce a
econdary response after they received an antigenic
ooster with inactivated FMDV. The secondary antibody
esponse in the recipient animals is induced only when
hese B-cells are cotransferred with FMDV presensitized
-cells and then boosted with the viral antigen (26). Only
hose synthetic peptides containing T-helper epitopes
ecognized in vivo will be able to sensitize functional
-helper cells. We used this assay then to detect which of
he sequences already described could function as a
-helper epitope in vivo.
FMDV-sensitized B-cells were obtained from mice im-
unized 20 days before the transfer experiment with 0.1
mg of inactivated FMDV in PBS. Spleen B-lymphocytes
were purified from these animals as described by Ber-
instein et al. (26). Peptide-sensitized spleen cells were
obtained 3 days after the last booster from animals that
had received three immunizations as described before,
eir Position within the Linear Sequence
Proteins VP2, VP3, and VP4
residue position Peptide VP and residue position
2 97–116 3.4 VP3 49–68
2 113–132 3.5 VP3 65–84
2 129–148 3.6 VP3 81–100
2 145–161 3.7 VP3 97–116
2 163–182 3.8 VP3 113–132
2 179–198 3.9 VP3 129–148
2 195–214 3.10 VP3 145–161
2 204–221 3.11 VP3 158–177
3 1–20 3.12 VP3 174–193
3 17–36 3.13 VP3 190–209
3 33–52 3.14 VP3 206–217ABLE 1
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236 RAPID COMMUNICATIONirradiation with X rays (500 Gy). The following day, each
recipient animal received 8 3 106 spleen B-cells from
donors immunized with 0.1 mg of inactivated FMDV and
6
FIG. 1. (A) Antibody (anti-peptide and anti-FMDV virus particles, both
immunized with the synthetic peptides. For the three assays, each colu
deviations are shown as error bars. ELISA titers are expressed as the lo
at least twice higher than a pool of normal mice sera at the same dilu
expressed as a stimulation index (SI) resulting from the ratio between
the mean of those with medium alone (SI values $3 were considered
the receptors of the passive cell-transfer experiment 10 days after the
individual. Mice from the experimental groups received 8 3 106 B-cells
cells from animals immunized with the peptide sequence indicated at
from control group III did not receive any cells. Titers are expressed a
D at least twice higher than the mean OD of the sera of the a
eptide-vaccinated animals) at the same dilution.0 3 10 total spleen cells from donors immunized with
ach of the different peptides. All recipient groups com-rised four animals and on the day of the cell-transfer, all
f them received an antigenic booster consisting of 2 mg
of inactivated FMDV in PBS. Three negative control
ed by ELISA) and cellular mediated immune response (ADLA) in mice
resents the mean of two or three different experiments and standard
he reciprocal of the highest serum dilution that produced OD readings
r the ADLA, cell cultures were performed in triplicate and results are
an of the cpm registered in cultures with the homologous peptide and
e). (B) Antibody titers against the complete FMDV particle induced in
r. Each bar represents the anti-FMDV ELISA titer of one experimental
ice immunized with 0.1 mg of inactivated FMDV and 40 3 106 spleen
tom. Animals from control group I received only B-cells, while animals
g10 of the reciprocal of the highest dilution of serum that produced an
from control group II (receptors receiving only spleen cells fromdetect
mn rep
g10 of t
tion. Fo
the me
positiv
transfe
from m
the bot
s the logroups were included in each passive cell-transfer ex-
periment: (I) animals that received only B-cells from in-
teins.
results.
237RAPID COMMUNICATIONactivated FMDV-immunized animals, (II) animals that re-
ceived only spleen cells from peptide-vaccinated ani-
mals, and (III) animals that did not receive any kind of cell
preparation. Among these groups, only control group II
showed significant background reactivity against the
complete FMDV particle in all the experiments per-
formed.
Ten days after the transfer, the sera of the recipient
animals were used to measure the specific anti-FMDV
antibody response in a capture ELISA with the whole
virus. Individual antibody titers of the animals in each
experimental group were expressed as the mean OD
readings of sera from the animals of control group II
(recipients receiving only spleen cells from peptide-vac-
cinated animals).
The results of the cell-transfer experiments indicated
that 7 of these 13 sequences were able to help the
production of antibodies (peptides 2.4, 2.8, 2.11, 2.12, 2.13,
3.9, and 4.2), thus showing their in vivo functionality (Fig.
1B). The ability of each sequence to stimulate the T-
helper activity was different, as reflected in the level of
FMDV antibodies elicited and in the number of positive
responding animals in each of the experimental groups.
In this way, peptides 4.2 (residues 17 to 36 of VP4), 2.8
(residues 113 to 132 of VP2), 2.12 (residues 179 to 198 of
VP2), and 3.9 (residues 129 to 148 of VP3) were more
efficient in exercising the T-helper function in the cell-
transfer assays.
In these experiments T-cells were obtained from do-
nors that had received their last peptide booster just 3
days before the transfer. Therefore it was important to
test whether these T- cells were already transferred in an
activated state or whether the activation occurred in the
recipient mice after the antigenic booster. Two of the
sequences (peptides 2.4 and 2.12), which had produced
positive responses but differing in potency, were used for
this purpose. The passive cell-transfer experiment was
essentially repeated in the same way, but employing total
spleen cells from peptide-vaccinated animals that had
received the last booster 20 days earlier (groups 2.4 b
FIG. 2. Diagram showing the location of the T-cell epitopes mappe
peptides within the amino acid sequence of the FMDV structural pro
cell-transfer assay for each of them. Filled positions indicate positiveand 2.12 b in Fig. 1B). The results showed no differences
in the values observed when the transfer was performed3 days after the last booster. This indicated that the
T-cells, rather than having been transferred in an acti-
vated state, had been activated in the recipient animal
after processing and presentation of the inactivated
FMDV included in the antigenic booster (Fig. 1B). A
summary of the results obtained for each of the tested
peptides in ELISA, ADLA, and the cell-transfer assays is
presented in Fig. 2.
Fusion peptide experiments. Sequences including T-
cell epitopes can help in the induction of antibodies
when fused to the N-terminus of peptides carrying B-cell
epitopes, as originally demonstrated by Partidos et al.
(14). We decided to test the ability of one of the se-
quences previously described, peptide 2.12 (179–198 of
VP2), to enhance the specific antibody response against
a low immunogenic but neutralizing FMDV VP1 epitope.
In previous publications (20–22) we described a 10-
residue sequence included in the FMDV VP1, spanning
amino acids 135 to 144 (p135-144 or p2) that contained
both B- and T-cell epitopes and we showed that the
antibodies directed against this sequence were able to
neutralize FMDV. Our results demonstrated that although
the p2 sequence by itself induced a low level of anti-
FMDV antibodies, the dimeric configuration of p2 con-
taining the sequence in tandem (p232) was capable of
inducing neutralizing antibody responses, which pro-
tected animals against FMDV challenge (22).
Here, peptide 2.12 was synthesized linked to the N-
terminus of the p2 sequence and the antibody levels
against p2 induced by the fusion peptide (p2.12–p2) were
compared with those elicited in animals immunized with
the p232.
Groups of five animals received a single immunization
with p232 or p2.12–p2 with a dose molar equivalent to 10
mg of p2. In all cases peptides were administered un-
coupled and diluted in PBS. Serum samples were ob-
tained 50 days postinoculation (dpi) and the specific
antibody titers against p135-160 and p2 were measured
using a direct ELISA. In Fig. 3 it is shown that the mean
2, VP3, and VP4. The upper bar indicates the position of the tested
The bars below show the results obtained in ELISA, ADLA, and thed in VPlevel of specific antibodies induced by the fusion peptide
p2.12–p2 against both the p135-160 and the p2 neutral-
p d one
c te the
238 RAPID COMMUNICATIONizing sequences was significantly higher than those elic-
ited in the p232-immunized animals.
Discussion. The first two groups of experiments
(ELISA and ADLA) showed the existence of 13 peptides
including T-cell epitopes: 6 from VP2, 6 from VP3, and 1
from VP4.
One of sequences (peptide 3.7) was positive by ADLA
and negative for ELISA, indicating the lack of B-cell
epitopes in its sequence. Peptides 4.2 and 2.4, on the
other hand, were positive for ELISA, but did not induce
lymphocyte proliferation. This could indicate that they
were toxic to cell cultures, but also reflects a higher
sensitivity in favor of the ELISA as a methodology to
detect T-cell epitopes. Finally, the results of the in vivo
passive cell-transfer experiments indicated that 7 of
these 13 sequences were biologically functional. The
actual existence of T-cell epitopes in the 4.2 and 2.4
peptides was also confirmed in these experiments.
Sequences included in peptides 2.4 (49–68 of VP2), 3.6
(81–100 of VP3), and 4.2 (20–40 of VP4) coincided with
the location of T-cell epitopes already described in other
FMDV strains (23, 24). However, the results presented
here demonstrated for the first time the existence, loca-
tion, and functionality of at least 10 unknown T-cell
epitopes in the structural proteins of FMDV VP2, VP3,
and VP4.
As was extensively described previously, protection to
FMDV is directly related to the level of antibodies di-
FIG. 3. Antibody titers elicited 50 dpi against the FMDV neutralizing
2.12–p2 (empty columns) or p232 (hatched columns). Animals receive
olumn represents the mean titer of five animals and error bars indicarected against the neutralizing sequences of the virus
(27, 28). We believe that our results with peptide p2.12coupled to the p2, improving those obtained by the al-
ready protective p232, constitute an interesting example
of the utilization of fine epitope mapping in an animal
model for the design of effective discrete synthetic im-
munogens.
Chimeric immunogens including B- and T-cell
epitopes from the FMDV should be able to induce neu-
tralizing antibodies upon vaccination and also be capa-
ble of priming memory cells. This would allow vaccinated
animals to rapidly activate protective responses once
they have contact with the natural viral agent in the field.
For this reason, and taking into account that sequences
from VP1 have already been studied for this purpose with
unsatisfactory results (9, 10, 18), it is important to identify
new T-cell stimulatory sequences included in the rest of
the structural proteins of FMDV. We believe that our
results may allow the development of novel immunogens
through the association of these new sequences with
other immunogenic regions that are naturally distant in
the virus structure.
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